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Zn2+ is concentrated into presynaptic vesicles at many central synapses and is released
into the synaptic cleft by nerve terminal stimulation. There is strong evidence that
synaptically released Zn2+ modulates glutamatergic neurotransmission, although there
is debate concerning the peak concentration it reaches in the synaptic cleft. Glycine
receptors (GlyRs), which mediate inhibitory neurotransmission in the spinal cord and
brainstem, are potentiated by low nanomolar Zn2+ and inhibited by micromolar Zn2+.
Mutations that selectively ablate Zn2+ potentiation result in hyperekplexia phenotypes
suggesting that Zn2+ is a physiological regulator of glycinergic neurotransmission. There
is, however, little evidence that Zn2+ is stored presynaptically at glycinergic terminals
and an alternate possibility is that GlyRs are modulated by constitutively bound Zn2+.
We sought to estimate the peak Zn2+ concentration in the glycinergic synaptic cleft
as a means of evaluating whether it is likely to be synaptically released. We employed
‘artificial’ synapses because they permit the insertion of engineered α1β GlyRs with
defined Zn2+ sensitivities into synapses. By comparing the effect of Zn2+ chelation
on glycinergic IPSCs with the effects of defined Zn2+ and glycine concentrations
applied rapidly to the same recombinant GlyRs in outside-out patches, we inferred that
synaptic Zn2+ rises to at least 1 µM following a single presynaptic stimulation. Moreover,
using the fast, high-affinity chelator, ZX1, we found no evidence for tonic Zn2+ bound
constitutively to high affinity GlyR binding sites. We conclude that diffusible Zn2+ reaches
1 µM or higher and is therefore likely to be phasically released in artificial glycinergic
synapses.
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INTRODUCTION
The free ionic form of zinc (Zn2+) is present in the extracellular CNS solution at low nM
concentrations (Frederickson et al., 2006). We define this as ‘tonic’ Zn2+. It is also concentrated
into presynaptic vesicles at many brain glutamatergic synapses (Frederickson, 1989) and is released
into the synaptic cleft by nerve terminal stimulation (Assaf and Chung, 1984; Howell et al., 1984).
The GluN2A-containing NMDA receptor (NMDAR) cation channels that populate these synapses
are inhibited by Zn2+ at low nM concentrations (Paoletti et al., 1997). Recent studies have found
evidence for the transient modulation of synaptic NMDARs by phasically released Zn2+ (Vergnano
et al., 2014; Anderson et al., 2015) and for the constitutive modulation of extrasynaptic NMDARs
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by tonic Zn2+ (Anderson et al., 2015). A major unresolved
question concerns the concentration to which Zn2+ rises during
synaptic activation, with estimates spanning four orders of
magnitude from 10 nM (Kay, 2003) to >100 µM (Vogt
et al., 2000). It is important to resolve this because many
neuronal membrane proteins are modulated by Zn2+ at high
concentrations (Marger et al., 2014), and a knowledge of the peak
Zn2+ concentration would permit the identification of potential
physiological targets of synaptically released Zn2+.
It is also unclear whether tonic or synaptically released
Zn2+ modulates neurotransmission at other synapses. Glycine
receptor (GlyR) chloride channels, which mediate inhibitory
neurotransmission in the spinal cord and brainstem (Lynch,
2004), are a likely candidate for Zn2+ modulation for several
reasons. First, the major synaptic α1β GlyR isoform is
extremely sensitive to Zn2+, with low (10–1000 nM) Zn2+
concentrations potentiating EC50 glycine-gated currents and
higher Zn2+ concentrations (3–300 µM) eliciting a dose-
dependent inhibition (Bloomenthal et al., 1994; Laube et al.,
1995; Miller et al., 2005a,b). Second, selectively ablating the
sensitivity of α1 GlyRs to Zn2+ potentiation led to impaired
glycinergic inhibition and a hyperekplexia-type phenotype in
α1D80A GlyR knock-in mice (Hirzel et al., 2006). Third, by
eliminating free Zn2+ from the synaptic cleft via Zn2+ buffers
and chelators, it has been shown that glycinergic inhibitory
post-synaptic currents (IPSCs) are positively modulated by
either tonic or synaptically released Zn2+ (Suwa et al.,
2001; Hirzel et al., 2006; Perez-Rosello et al., 2015). Fourth,
there is strong evidence for the co-localization of Zn2+
and glycine at presynaptic terminals in the spinal cord of
the lamprey (Birinyi et al., 2001) although the evidence for
their co-localization at glycinergic presynaptic terminals in the
mammalian spinal cord is less clear cut (Wang et al., 2001).
However, to date there has been no investigation into the
possibility that Zn2+ may be phasically released at glycinergic
synapses.
Since glycine reaches a saturating concentration in the cleft
during synaptic stimulation (Legendre, 1998; Beato, 2008),
potentiating concentrations of Zn2+ cannot further increase the
IPSC magnitude, and as a result Zn2+ potentiation is manifest as
a slowing in the IPSC decay rate (Suwa et al., 2001; Laube, 2002;
Hirzel et al., 2006; Eto et al., 2007). However, miniature IPSCs,
which are mediated by the stochastic release of single glycine
vesicles and thus involve sub-saturating glycine concentrations,
are increased in magnitude by potentiating concentrations of
Zn2+ (Suwa et al., 2001; Hirzel et al., 2006; Perez-Rosello et al.,
2015).
We have recently developed an ‘artificial’ synapse system
whereby glycinergic synapses are induced to form between
presynaptic terminals of cultured spinal glycinergic interneurons
and HEK293 cells expressing recombinant heteromeric GlyRs
(Dixon et al., 2015; Zhang et al., 2015). This system has two
main advantages over neuronal synapses. First, it allows control
over the subunit composition of post-synaptic GlyRs. Second, the
electrotonically compact shape of HEK293 cells avoids problems
associated with dendritic filtering, allowing IPSC waveforms to
be resolved with high fidelity. In the present study, we engineered
the Zn2+ sensitivities of recombinant GlyRs so that they could
act as reporters of synaptic Zn2+ over different concentration
ranges. By comparing the effect of Zn2+ chelation on IPSCs
with the effects of buffered Zn2+ plus glycine concentrations
applied rapidly to the same recombinant GlyRs to simulate
synaptic activation, we sought to provide an estimate of the
concentration to which Zn2+ rises in response to a single
presynaptic stimulation.
MATERIALS AND METHODS
Molecular Biology and HEK293 Cell
Transfection
We employed plasmid DNAs encoding the human α1 (pCIS),
rat α3L (pcDNA3.1) and human β (pcDNA3.1) GlyR subunits,
plus mouse neuroligin 2A (pNice) and rat gephyrin P1 (pCIS).
Empty pEGFP plasmid was also transfected as an expression
marker. Site-directed mutagenesis was performed using the
QuikChange mutagenesis kit (Agilent Technologies) according
to manufacturers’ instructions and the successful incorporation
of mutations was confirmed by DNA sequencing. The plasmid
DNAs were transfected into HEK293 cells via a calcium
phosphate-DNA co-precipitation protocol. When expressing
α1β GlyRs, we transfected the following DNA quantities into
each 35 mm culture dish of HEK293 cells: 0.03 µg α1 GlyR,
1.5 µg β GlyR, 0.2 µg neuroligin 2A, 0.2 µg gephyrin,
0.1 µg EGFP. When expressing α3β GlyRs, we transfected
the following DNA quantities into each 35 mm culture dish:
0.15 µg α3L GlyR, 1.5 µg β GlyR, 0.2 µg neuroligin 2A, 0.2 µg
gephyrin, 0.1 µg EGFP. We have previously validated that these
transfection conditions result in a high level of expression of
heteromeric α1β and α3β GlyRs, respectively (Zhang et al.,
2015).
Artificial Synapse Formation
Details of this method have recently been published (Dixon et al.,
2015; Zhang et al., 2015). Briefly, E15 timed-pregnant rats were
euthanized via CO2 inhalation in accordance with procedures
approved by the University of Queensland Animal Ethics
Committee (approval number: QBI/203/13/ARC). Embryos were
surgically removed and placed into ice cold Ca2+-Mg2+-free
Hank’s Balanced Salt Solution under sterile conditions. The spinal
cords were then dissected out and pinned at the wider proximal
end while meninges were carefully detached. The dissected
neurons were then triturated, centrifuged and resuspended in
Dulbecco’s Modified Eagles Medium supplemented with 10%
fetal bovine serum. Between 40,000 and 80,000 neurons were
plated onto each 12 mm poly-D-lysine-coated coverslip in 4-
well plates. Neuronal cultures were always maintained in a
5% CO2 incubator at 37◦C. After incubation for 24 h the
entire Dulbecco’s Modified Eagles Medium supplemented plus
10% fetal bovine serum medium was replaced with Neurobasal
medium including 2% B27 and 1% GlutaMAX supplements.
A second (and final) feed 1 week later replaced half of
this medium. Neurons were used in co-culture experiments
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1–4 weeks later. Heterosynaptic co-cultures were prepared
by directly introducing transfected HEK293 cells onto the
primary neuronal cultures 1-3 days prior to electrophysiological
recording.
Electrophysiology
All experiments were performed at 20–22◦C at a holding
potential of −60 mV. Whole-cell recordings were obtained
with a HEKA EPC10 amplifier (HEKA Electronics, Lambrecht,
Gremany) and Patchmaster software (HEKA), with currents
filtered at 4 kHz and sampled at 10 kHz. Series resistance
was compensated to 60% and monitored throughout the
recording. Patch pipettes (4–8 M) made from thick-
walled borosilicate glass (GC150F-7.5, Harvard Apparatus)
were filled with an internal solution comprising (in mM):
145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA and
2 MgATP, pH 7.4 with NaOH. Cells were perfused with
extracellular solution comprising (in mM): 140 NaCl, 5 KCl,
2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, pH 7.4 with
NaOH.
For outside-out recordings, pipettes were fired-polished to
a resistance of ∼10 M and filled with the same internal
solution. Macroscopic currents in outside-out patches pulled
from transfected HEK293 cells were activated by brief (<1 ms)
exposure to agonists using a piezoelectric translator (Siskiyou).
Currents were recorded using a Multiclamp 700B amplifer and
pClamp10 software (Molecular Devices), filtered at 4 kHz and
sampled at 10 kHz.
In accordance with standard practice in the field, solutions
containing buffered concentrations of free Zn2+ were made by
adding 10, 100, 500, and 1000 µM free Zn2+ to the standard
extracellular solution + 10 mM tricine (Sigma-Aldrich) to
produce buffered Zn2+ concentrations of 0.1, 1, 5, and 10 µM,
respectively (Paoletti et al., 1997; Low et al., 2000; Miller et al.,
2005b; Vergnano et al., 2014). The added Zn2+ concentration
was aliquoted from a 10 mM aqueous ZnCl2 stock solution on
the day of the experiment. ZX1 (Strem Chemicals) was dissolved
as a 100 mM stock in water and added to the control solution on
the day of the experiment.
Data Analysis
Analyses of IPSC amplitudes, 10-90% rise times and decay
time constants were performed using Axograph X (Axograph
Scientific). Single peak IPSCs with amplitudes of at least
three times the background noise were detected using
a semi-automated sliding template. Events were visually
inspected and only well-separated IPSCs with no inflections
in the rising or decay phases were included. Current decay
phases were fitted with double-exponential functions and a
weighted time constant was calculated from individual time
constants (τ1, τ2) and their relative amplitudes (A1,A2) as
follows: τweighted = (τ1 × A1+τ2 × A2)/(A1+A2). Statistical
comparisons were performed using non-parametric tests
(Prism 6, GraphPad Software, Inc.). For multiple comparisons
we used either the Friedman test or the Wilcoxon matched-
pairs signed rank test and for single comparisons we used
the Mann–Whitney U-test. In all tests we took p < 0.05
to be statistically significant. All displayed error bars
represent SEM.
RESULTS
Zn2+-Sensitivity of IPSCs Mediated by
α1β, α1H107Nβ, and α1W170Sβ GlyRs
The α1β GlyR is the main synaptic isoform (Lynch, 2009).
Zn2+ potentiates EC50 glycine-gated currents in recombinant
α1β GlyRs with an EC50 near 40 nM (Miller et al., 2005b) and
inhibits with an IC50 near 13 µM (Miller et al., 2005a). We also
investigated the α1H107Nβ and the α1W170Sβ GlyRs. The H107N
mutation eliminates Zn2+ inhibition and increases the Zn2+
potentiation EC50 to 0.8 µM (Miller et al., 2005b). We reasoned
that this receptor should respond only to high nanomolar or
micromolar concentrations of Zn2+. The W170S mutation,
which occurs naturally in a sporadic case of human hyperekplexia
(Al-Futaisi et al., 2012), eliminates Zn2+ potentiation but leaves
Zn2+ inhibition intact with an IC50 near 5 µM (Zhou et al.,
2013). We employed this mutant as both a negative control
for the potentiating effect of Zn2+ and to determine whether
Zn2+ inhibition (when isolated from potentiation) is capable of
affecting IPSC parameters.
In order to precisely control the extracellular Zn2+
concentration, we buffered it with 10 mM tricine as described in
Section “Materials and Methods.” We also applied 10 mM tricine
with no added Zn2+ to buffer the free Zn2+ concentration to
virtually zero, although as recently demonstrated for NMDARs,
this may not remove tonic Zn2+ that is bound constitutively
to low nanomolar affinity Zn2+ binding sites (Anderson et al.,
2015). Thus, our starting hypothesis is that 10 mM tricine
ablates freely diffusing Zn2+ but not constitutively bound
Zn2+.
Sample recordings of spontaneous IPSCs from HEK293 cells
expressing the indicated constructs are shown in Figure 1A. As
these IPSCs were almost entirely abolished by 1 µM tetrodotoxin
(not shown), we infer they were induced by spontaneous
action potentials. The remaining miniature IPSCS were too
small to analyze. Figure 1A (left) shows sample recordings
of spontaneous IPSCs recorded from single cells expressing
either the α1β GlyR (top), the α1H107Nβ GlyR (middle) or
the α1W170Sβ GlyR (bottom). The left panels show control
recordings in tricine-free extracellular solution, the center panels
show the effect of 10 mM tricine and the right panels show
the effect of adding 5 µM free Zn2+. Individual IPSCs from
the recordings in A were normalized and digitally averaged
to produce the global mean IPSC waveforms as displayed in
Figure 1B. The mean IPSC amplitudes, decay time constants
and 10–90% rise times for each construct recorded in tricine-
free extracellular solution are presented in Figure 1C. We found
that IPSCs mediated by α1W170Sβ GlyRs exhibited significantly
larger amplitudes, longer decay time constants and slower rise
times relative to those mediated by α1β GlyRs. This indicates
that the W170S mutation affects intrinsic receptor gating or
synaptic clustering properties in addition to ablating Zn2+
potentiation.
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FIGURE 1 | Effects of synaptic Zn2+ on spontaneous IPSCs mediated by α1β, α1H107Nβ, and α1W170Sβ GlyRs. (A) Representative recordings of IPSCs
mediated by the indicated constructs are shown in the presence of tricine-free solution (black traces), 10 mM added tricine (red traces) and 10 mM added tricine +
500 µM added Zn2+ ( =5 µM free Zn2+: blue traces). (B) Superimposed, digitally averaged, normalized IPSCs from the corresponding cell in (A). The total number
of events included in each averaged IPSC was as follows: α1β GlyR (control: 86; 10 mM added tricine: 63; 10 mM added tricine + 500 µM added Zn2+: 92),
α1H107Nβ GlyR (control: 72; 10 mM added tricine: 56; 10 mM added tricine + 500 µM added Zn2+: 89), α1W170Sβ GlyR (control: 53; 10 mM added tricine: 61;
10 mM added tricine + 500 µM added Zn2+: 68). (C) Comparison of mean IPSC amplitude, decay time constant and 10–90% rise time for the three constructs in
tricine-free solution. Statistical significance was determined by Mann–Whitney U-test. The distributions in WT and W170S values differed significantly for amplitude
(Continued)
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FIGURE 1 | Continued
(U = 11, ∗p < 0.05), decay time constant (U = 0, ∗∗∗p < 0.001) and 10–90% rise time (U = 10, ∗p < 0.05). (D–F) Comparison of the effects of the indicated
solutions on IPSC amplitude, decay time constant and 10–90% rise time for the three constructs. Comparisons between the constructs are not shown. Statistical
significance was determined by Friedman test with significance represented by ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Relative to their values in
10 mM tricine, the decay time constants for α1β and α1H107Nβ GlyRs increased by 74 ± 13% and 50 ± 24%, respectively, in standard extracellular solution and by
109 ± 15% and 101 ± 28%, respectively, in 5 µM free Zn2+. We analyzed 12 cells expressing α1β GlyRs, seven cells expressing α1H107Nβ GlyRs and five cells
expressing α1W170Sβ GlyRs.
Figures 1D–F summarizes the effects of adding either 10 mM
tricine alone or 5 µM free Zn2+ to IPSCs mediated by the
three constructs. We observed no effect 10 mM tricine on
the IPSC amplitude mediated by any construct (Figure 1D).
However, the removal of free Zn2+ significantly accelerated the
decay rate of α1β GlyRs (Figure 1E) indicating that the free
Zn2+ concentration is high enough to positively modulate these
receptors. In contrast, 10 mM tricine had no effect on the IPSC
decay rate mediated by α1W170Sβ GlyRs. This not only provides
a control for the GlyR-specificity of the Zn2+ potentiating
effect, but also indicates that the low affinity inhibitory effect
of Zn2+ does not appreciably affect IPSC parameters. All these
findings are reinforced by the converse experiment whereby
increasing free Zn2+ to 5 µM significantly slowed the decay
rate in α1β GlyRs and α1H107Nβ GlyRs but had no effect
on α1W170Sβ GlyRs (Figure 1E). The removal free Zn2+ also
accelerated the rise times of IPSCs mediated by α1β GlyRs only
(Figure 1F).
Zn2+-Sensitivity of IPSCs Mediated by
α3β GlyRs
In an attempt to generalize our findings, we investigated the
Zn2+-sensitivity of the other major adult synaptic GlyR isoform,
the α3β, which mediates synaptic inhibition onto nociceptive
neurons in superficial laminae of the adult spinal cord dorsal
horn (Zeilhofer et al., 2012). Despite their importance in pain
signal processing mechanisms and their relevance as novel
therapeutic targets for inflammatory pain (Lynch, 2009; Zeilhofer
et al., 2012), the Zn2+ sensitivity of α3β GlyRs has never been
investigated. We thus repeated the experiment of Figure 1A
on spontaneous IPSCs mediated by α3β GlyRs. Examples of
normalized, averaged IPSCs recorded from one cell exposed
sequentially to standard extracellular solution containing no
tricine, 10 mM tricine, or 10 mM tricine plus 5 µM free Zn2+
are shown in Figure 2A, with averaged results summarized
in Figures 2B–D. According to the non-parametric Friedman
test, these data reveal that the removal of free Zn2+ by
10 mM tricine had no significant effect on any IPSC parameter.
However, as all data distributions in Figure 2B satisfied the
D’Agostino-Pearson omnibus test for normality (using p < 0.05
as cutoff), we performed a repeated measures one-way ANOVA
on decay time constants of the control versus 10 mM tricine and
10 mM tricine plus 5 µM free Zn2+ experimental conditions.
As 10 mM tricine significantly accelerated the IPSC decay
rate according to this test (p < 0.05, n = 8), we conclude
that the endogenous levels of Zn2+ in artificial synapses
significantly prolong the decay time constant of α3β GlyR-
mediated IPSCs.
FIGURE 2 | Effects of synaptic Zn2+ on IPSCs mediated by α3β GlyRs.
(A) Superimposed averaged, normalized IPSCs each averaged from >50
events from the same cell. Recordings were made in the presence of
tricine-free solution (black trace; averaged from 52 events), 10 mM added
tricine (red trace; averaged from 55 events) and 10 mM added tricine +
500 µM added Zn2+ ( =5 µM free Zn2+: blue trace; averaged from 83
events). (B–D) Comparison of the effects of the indicated solutions on IPSC
amplitude, decay time constant and 10–90% rise time for α3β-mediated
IPSCs. All results were averaged from eight cells. Statistical significance was
determined by Friedman test with significance represented by ∗∗∗p < 0.001.
Calibrating the Zn2+-Sensitivity of α1β,
α1H107Nβ, and α1W170Sβ GlyRs under
Simulated Synaptic Activation
Conditions
The α1β GlyR Zn2+ EC50 and IC50 values cited above were
obtained under steady-state applications of Zn2+ and EC50
glycine (Miller et al., 2005a,b). As these conditions do not
apply to the synapse, we calibrated the Zn2+ sensitivity of
the GlyR constructs using fast solution exchange to mimic
synaptic activation conditions. The glycine concentration in the
synaptic cleft has been estimated to reach a peak of 1–3 mM
in embryonic zebrafish hindbrain neurons (Legendre, 1998) and
2.2–3.5 mM in adult rat spinal motor neurons (Beato, 2008).
Glycine is cleared from the cleft with a time constant of 0.6–
0.9 ms (Beato, 2008). Considering these parameters, we simulated
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synaptic activation conditions by applying 1 mM glycine with
or without free Zn2+ for 0.5–1 ms to outside-out macropatches
expressing the GlyR isoform of interest. To calibrate and optimize
the solution application system, we rapidly switched the solution
perfusing an open patch pipette between standard extracellular
solution and an extracellular solution that had been diluted by
50% with distilled water. Figure 3A shows an example of an
open pipette response, indicating the typical solution exposure
profile. We performed this control regularly to ensure that the
solution switching rate remained constant within and between
experiments.
Contaminating Zn2+ released into solution from plastic
and glass laboratory ware is thought to reach concentrations
as high as 100 nM (Kay, 2004), which is high enough to
modulate steady-state GlyR currents activated by low glycine
concentrations (Miller et al., 2005b; Cornelison and Mihic,
2014). We determined whether Zn2+ contamination might have
contributed to the results of Figures 1 and 2 via two sets
of control experiments. The first involved switching rapidly
between a control (putatively Zn2+-contaminated) solution and
a Zn2+-chelating solution. In this experiment the control and
test solutions both comprised our standard extracellular solution
plus 1 mM glycine, although the test solution also contained
either 10 mM tricine or 100 µM ZX1 (Perez-Rosello et al.,
2015). A sample recording from a single macropatch containing
α1β GlyRs suggests the chelators had little effect on decay rate
(Figure 3B) and the averaged result confirms the lack of a
significant effect on either the decay or rise times (Figures 3C,D).
It is evident, however, that ZX1 showed a tendency to decrease
the decay time constant that may become significant with a larger
number of observations. If so, this effect could be due to either (1)
a direct allosteric inhibitory effect on the GlyR or (2) the removal
of tonically bound Zn2+ from the GlyR. The second possibility
will be investigated below.
In a second control experiment, we initially exposed
macropatches to a buffered 100 nM Zn2+ solution and switched
this rapidly to either a control (putatively Zn2+-contaminated)
solution (n = 10 macropatches) or to a Zn2+-chelating solution
(i.e., control + 10 mM tricine, n = 3 macropatches). Again, no
significant differences in rise times or decay rates were observed
in either experiment (p > 0.05 by Mann–Whitney U-test).
Together, these results strongly suggest that contaminating Zn2+
in our extracellular solution had no significant effect on IPSC rise
or decay rates.
To mimic synaptic activation, we employed standard
extracellular solution without added tricine as the control
solution to replicate the conditions employed in Figures 1 and 2.
Test solutions had the same composition except that we added
1 mM glycine either alone or together with 10 mM tricine and
100 nM, 1 or 10 µM free Zn2+. Examples of current responses
to the sequential application of each of these four solutions to
α1β, α1H107Nβ, and α1W170Sβ GlyRs are shown in Figure 4A,
with averaged weighted deactivation time constants shown in
Figure 4B. The averaged individual time constants (τ1, τ2)
and their relative amplitudes (A1, A2) for each experimental
condition are presented in Supplementary Table S1. For the α1β
GlyR, we observed no change in the deactivation rate or 10–90%
rise time at 100 nM Zn2+. We observed a statistically significant
FIGURE 3 | Control experiments employing rapid solution exchange over macropatches expressing α1β GlyRs. (A, left) Image of the double-barrelled
2-tube used to perform the rapid solution exchange experiments on macropatches. The image also shows an open recording pipette and the position of the
solution interface (broken line). (Right) Open pipette response obtained by switching the solution over the electrode tip from the standard extracellular solution to one
diluted to 50% with water. The rise and decay times are approximately 300 µs. (B) Overlayed macropatch recordings (averages of 6–20 sweeps) of control (black,
1 mM glycine) and co-application of 1 mM glycine with either 10 mM tricine (red) or 100 µM ZX1 (green). (C) Summary bar plots of the weighted decay time constant
for control and the two Zn2+ chelators. (D) Summary bar plots of the rise times for control and the two Zn2+ chelators. Mann–Whitney U-test revealed no significant
differences in the distributions of either the decay or rise times, p > 0.05 for both, n = 3–8 macropatches for each condition.
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slowing in the deactivation rate at 1 µM and a dramatic slowing
in deactivation rate at 10 µM free Zn2+. We also observed a
statistically significant slowing in the deactivation rate at 10 µM
free Zn2+at the α1H107Nβ GlyR. At 10 µM Zn2+, the percentage
increase in the macropatch current deactivation time constant
at both receptors (α1β: 76 ± 41%; α1H107Nβ: 76 ± 19%) was
comparable to the magnitude of the IPSC decay time constant
increase from 10 mM tricine-containing to standard extracellular
solution (α1β: 74 ± 13%, α1H107Nβ: 50 ± 24%). In contrast, at
the α1W170Sβ GlyR we observed no change in IPSC magnitude,
decay rate or rise time at free Zn2+ concentrations up to 10 µM
(Figures 4A–C). Together, these results suggest that the free
synaptic Zn2+ concentration reaches a concentration of at least
1 µM following a single synaptic stimulation. The lack of an
inhibitory effect of 10 µM Zn2+ on α1W170Sβ GlyRs is most
likely due to a combination of the slow onset of Zn2+ inhibition
and the brief exposure time to Zn2+ under synaptic stimulation
conditions.
We next considered the possibility that the magnitude of the
Zn2+ effect may depend on the synaptic glycine concentration.
We therefore repeated the experiment of Figure 4A at α1β
GlyRs using 3 mM glycine, in line with the maximum predicted
synaptic glycine concentration (Legendre, 1998; Beato, 2008).
Sample recordings reveal that 10 µM Zn2+ exerts a diminished
prolonging effect on deactivation rate of currents activated by
brief applications of 3 mM glycine (Figure 4C). This trend is
supported by the averaged data shown in Figure 4D. Thus, if the
concentration of glycine in the synaptic cleft is 3 mM or higher,
our results imply that Zn2+ must rise to concentrations greater
than 10µM during synaptic transmission to account for the effect
of 10 mM tricine on the IPSC decay rate.
Effect of a Fast, High-Affinity Zn2+
Chelator on IPSC Parameters
ZX1 is a fast, high affinity Zn2+ chelator (Radford and Lippard,
2013). When applied at a concentration of 100 µM, it has been
shown to efficiently remove tonic Zn2+ bound constitutively
to NMDARs (Anderson et al., 2015). Given that GlyRs and
NMDARs both have high affinity Zn2+ sites with similar
nanomolar affinities, it is reasonable to hypothesize that ZX1
FIGURE 4 | Calibration of the Zn2+-sensitivity of α1β, α1H107Nβ, and α1W170Sβ GlyRs under simulated synaptic activation conditions. (A) Representative
macropatch currents mediated by indicated constructs upon switching from control extracellular solution to one containing 1 mM glycine plus 10 mM tricine plus the
indicated concentration of free Zn2+. Traces were averaged from >10 sweeps each and normalized. (B) Mean values for weighted decay time constants and
10–90% rise times for the three constructs. See Supplementary Table S1 for a full breakdown of n values, mean τ1 and τ2 values and their relative proportions.
Statistical significance was determined by Mann–Whitney U-test. The distributions in WT (glycine only) and WT (glycine + 1 µM Zn2+) values differed significantly for
decay time constant (U = 63, ∗p < 0.05, n1 = 17 macropatches, n2 = 13 macropatches). The distributions in WT (glycine only) and WT (glycine + 10 µM Zn2+)
values also differed significantly for decay time constant (U = 20, ∗∗∗p < 0.001, n1 = 17 macropatches, n2 = 10 macropatches). The distributions in H107N (glycine
only) and H107N (glycine + 10 µM Zn2+) values also differed significantly for decay time constant (U = 16, ∗∗p < 0.01, n1 = 13 macropatches, n2 = 8
macropatches). (C) Representative macropatch currents mediated by α1β GlyRs upon switching from control extracellular solution to one containing 3 mM glycine
plus 10 mM tricine plus the indicated free Zn2+ concentration. Traces were averaged from >10 sweeps each and normalized. (D) Mean values for weighted decay
time constant and 10–90% rise time for two glycine concentrations. Statistical significance was determined by Mann–Whitney U-test. The distributions in the 1 and
3 mM glycine 10–90% rise time values differed significantly for Zn2+ concentrations of 0, 100 nM and 1 µM (U = 9–15, ∗p < 0.05, n1 = 10–17 macropatches,
n2 = 5 macropatches).
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might act similarly on GlyRs. Indeed, a recent study suggested
that ZX1 removes tonic Zn2+ bound to synaptic GlyRs (Perez-
Rosello et al., 2015). We investigated the effects of 100 µM
ZX1 on IPSCs mediated by α1β GlyRs both as a control for
possible non-specific (e.g., pharmacological) effects of tricine and
to investigate the possibility that tonic Zn2+ might be bound
constitutively to synaptic GlyRs. Figure 5A shows examples
of normalized, averaged IPSCs recorded from one cell before,
during and after exposure to 100 µM ZX1. Results averaged from
nine cells recorded under identical conditions reveal that 100 µM
ZX1 had no significant effect on IPSC amplitude (Figure 5B) or
10–90% rise time (Figure 5C) although it significantly reduced
the IPSC decay time constant (Figure 5D). However, there
was no significant difference in the magnitude of the effect
of 10 mM tricine and 100 µM ZX1 on the IPSC decay time
constant (Figures 5E–G). Moreover, in five cells where we
quantitated the effects of 10 mM tricine and 100 µM ZX1
sequentially in the same cell, we found the ZX1 exerted no
significant additional effect on the IPSC decay time constant (not
shown). Thus, if tonic Zn2+ is bound constitutively to synaptic
α1β GlyRs in our artificial synapses, then its removal has no
functional consequence. We thus infer that the effect of tricine
and ZX1 on glycinergic IPSCs is mediated by freely diffusing
Zn2+.
In a final experiment, we quantitated the recovery time
course of IPSC decay time constant following ZX1 washout
(Figure 5H). In this experiment we digitally averaged all IPSCs
that occurred within each 30 s interval and fitted a single decay
time constant to the averaged waveform. Results were averaged
from five cells. As seen in Figure 5H, complete recovery from
ZX1 application required around 1 min, although the decay time
constant eventually stabilized at a value significantly higher than
the initial control IPSC decay time constant (Figures 5D,H). The
recovery from ZX1 inhibition suggests that the concentration
FIGURE 5 | Effects of 100 µM ZX1 on IPSCs mediated by α1β GlyRs. (A) Superimposed averaged, normalized IPSCs each averaged from >50 events from the
same cell. Recordings were made in the presence of control solution (black trace; averaged from 79 events), after addition of 100 µM ZX1 (red trace; averaged from
61 events) and after 5 min washout (pink trace; averaged from 52 events). (B–D) Effects of 100 µM ZX1 on IPSC amplitude, decay time constant and 10–90% rise
time for α1β-mediated IPSCs. All results were averaged from 10 cells. Statistical significance in (D) was determined by Friedman test with significance represented
by ∗p < 0.05, and ∗∗∗∗p < 0.0001. (E–G) Comparison of the effects of 10 mM tricine and 100 µM ZX1 on IPSC amplitude, decay time constant and 10–90% rise
time for α1β-mediated IPSCs. There was no significant difference in the decay time constants in either condition. Statistical significance in (G) was determined by
two-tailed Wilcoxon matched-pairs signed rank test, with significance represented by ∗∗p < 0.01 and ∗∗∗p < 0.001. (H) Time course of washout of the ZX1 effect
on decay time constant. ZX1 was applied for 3 min. All data points were averaged from five cells.
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of free synaptic Zn2+ is not depleted over time under our
experimental conditions.
DISCUSSION
The main advantage of our artificial synapse system is that it
allows control over the GlyR subunit composition. However, a
potential limitation is that artificial synapses may not faithfully
replicate real synapses, especially in terms of synaptic cleft
geometry or the location and density of Zn2+ and glycine
transporters. Although, such factors could affect Zn2+ and
glycine concentrations in the synaptic cleft, we think they are
unlikely to seriously compromise our conclusions for several
reasons. First, IPSCs from artificial synapses containing α1β
and α2β GlyRs exhibit decay times that are remarkably similar
to those from native neuronal synapses expressing the same
isoforms (Zhang et al., 2015). Second, the decay time constants of
IPSCs recorded in vitro from homozygous α1D80A knock-in mice
(where Zn2+ potentiation is abolished) or from homozygous
Spasmodic α1A52S mice (where glycine sensitivity is reduced
10-fold) were quantitatively similar to those recorded from
artificial synapses incorporating the same mutant subunits
(Graham et al., 2006; Hirzel et al., 2006; Zhang et al., 2015).
These results suggest a reasonably close correspondence in the
concentration profiles of Zn2+ and glycine between artificial and
real glycinergic synapses. Turning to the present study, tricine-
mediated buffering of extracellular Zn2+ significantly accelerated
the decay rate of IPSCs mediated by α1β and α1H107Nβ GlyRs.
However, no change in IPSC amplitude was observed. Together
these results imply that the Zn2+ concentration in the synaptic
cleft is high enough to modulate IPSCs, and that the glycine
concentration is saturating. These observations fit well with
previous studies on neuronal glycinergic synapses. For example,
a study that investigated glycinergic IPSCs in zebrafish neurons
found that 10 mM tricine reduced IPSC duration to a similar
extent as observed here (Suwa et al., 2001). In addition, studies by
Legendre (1998) and Beato (2008) found that the synaptic glycine
concentration reaches>1 mM, which is saturating at α1β GlyRs.
By comparing the effects of 10 mM tricine on IPSCs to the
effects of co-applied glycine plus free Zn2+ to macropatches, we
infer that the free synaptic Zn2+ rises to at least 1 µM following
a single action potential. The dramatic slowing in the IPSC
decay rate that we observed in the presence of 5 µM free added
Zn2+ (Figure 1E) is probably due to the total (experimentally
applied plus synaptically released) free Zn2+ rising to≥6 µM. In
addition, the absence of any effect of Zn2+ at concentrations up to
10 µM in the α1W170Sβ GlyR suggests that the well-characterized
inhibitory effect of Zn2+ (Laube et al., 1995; Nevin et al., 2003;
Miller et al., 2005a) is not physiologically relevant, at least at
low synaptic stimulation rates. Finally, given the similarity in the
effects of 10 mM tricine and 100 µM ZX1 on the IPSC decay
rate (Figure 5G), we find no evidence for tonic Zn2+ binding
constitutively to high affinity sites on the GlyR (Perez-Rosello
et al., 2015).
It is yet to be demonstrated that Zn2+ is co-released with
glycine in a phasic manner. However, in the absence of a
phasic release mechanism it is difficult to explain how a
≥1 µM Zn2+ concentration could be maintained in the cleft for
periods typically exceeding 20 min (Figure 5H) when the bulk
extracellular (tonic) concentration is presumably in the low nM
range (Frederickson et al., 2006).
A similar type of analysis of synaptic Zn2+ concentration
was recently performed on glutamatergic synapses (Vergnano
et al., 2014). GluN2A-containing NMDARs exhibit both high
affinity Zn2+ inhibition in the 10–20 nM range and low
affinity inhibition in the 10–50 µM range (Paoletti et al., 1997).
Vergnano et al. (2014) compared the effect of 10 mM tricine
on GluN2A-mediated synaptic currents from control mice to
those from knock-in mice that overexpressed a mutant GluN2A
deficient in high affinity Zn2+ binding. They found no effect
of tricine on single action potential-mediated excitatory post-
synaptic currents (EPSCs) in either case, although fast repetitive
stimulation unveiled Zn2+-mediated inhibition of EPSCs in
control animals only. From this they concluded that synaptic
Zn2+ does not rise high enough to bind to the low affinity sites. It
is noteworthy that α1β GlyRs and GluN2A-containing NMDARs
have similar high affinities to Zn2+. Given that a single action
potential releases sufficient Zn2+ to modulate glycinergic IPSCs
but not NMDAR-mediated EPSCs, we infer that Zn2+ rises to
significantly higher concentrations in the glycinergic synaptic
cleft. Indeed, high affinity chelation of Zn2+ by 100 µM ZX1 to
remove tonic Zn2+ bound to NMDARs is needed to detect an
effect of Zn2+ released by a single action potential (Anderson
et al., 2015). This implies that the Zn2+ concentration increase
in the glutamatergic synaptic cleft response to a single action
potential is in the low nM range.
GlyRs are also potentiated by La3+, Pb2+, and Co2+ and
inhibited by Cu2+ and Ni2+ (Lynch, 2004). As tricine is a
low affinity chelator with poor specificity among heavy metals
(Ferreira et al., 2015), it is possible that its effect of GlyRs may be
due to the chelation of other metal contaminants in the recording
solution. Since tricine inhibits glycinergic currents, we infer that
any metal contaminant must be a GlyR potentiator. However, the
three known potentiators (La3+, Pb2+, and Co2+) are unlikely
to be present as contaminants in our recording solutions at
concentrations high enough (100 µM) to positively modulate
GlyRs. Thus, it is highly likely that the effects of tricine on α1β
GlyR-mediated IPSCs is mediated by Zn2+. The selectively profile
for ZX1 among heavy metals is not known.
Human hyperekplexia, or startle disease, is most commonly
caused by hereditary mutations in α1 or β GlyR subunits that
disrupt glycinergic neurotransmission (Bode and Lynch, 2014).
Most startle mutations result in the complete or partial loss of
glycinergic inhibitory function (Chung et al., 2010; Bode et al.,
2013; Bode and Lynch, 2014). Given that the human α1W170S
startle mutation abolished Zn2+ potentiation, it was originally
concluded that the startle phenotype was due to a diminished
IPSC magnitude or duration (Zhou et al., 2013). In support of
this, a startle phenotype had previously been demonstrated in a
knock-in mouse overexpressing a mutant α1D80A GlyR subunit
in which Zn2+ potentiation had been eliminated (Hirzel et al.,
2006). Our fast application experiments demonstrate that the
inherent deactivation rates of α1β and α1W170Sβ GlyRs in the
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absence of Zn2+ are similar (Figure 4B), implying that the loss
of Zn2+ potentiation in α1W170Sβ GlyRs may indeed lead to a
net diminished current carrying capacity. However, in artificial
synapses we found that both the mean amplitude and decay rate
of IPSCs mediated by α1W170Sβ GlyRs were comparable to those
of α1β GlyRs that had been maximally positively modulated by
Zn2+ (Figures 1C,E). This effect could either be due to altered
gating properties or differential clustering at the synapse. We have
recently shown that the α1W170Sβ GlyR also exhibits spontaneous
activation (Zhang et al., 2016) and suggested that, like other gain-
of-function startle disease mutations, W170S may cause startle
disease via a developmental defect that prevents the maturation
of α1β GlyR synapses (Zhang et al., 2016).
CONCLUSION
We infer that the free Zn2+ concentration in the artificial
glycinergic synaptic cleft reaches at least 1 µM following a single
presynaptic stimulation. As this concentration is at least an
order of magnitude higher than the tonic Zn2+ concentration,
we assume that diffusible Zn2+ is somehow concentrated in
the synaptic cleft. The most likely explanation is that Zn2+ is
phasically released from presynaptic terminals. It is noteworthy
that this peak concentration is significantly higher than that
reached under similar conditions in the glutamatergic synaptic
cleft. We also found no evidence for tonic Zn2+ binding
constitutively to high affinity GlyR sites. Similarly, we found
no evidence for Zn2+ inhibition in response to a single
action potential in synapses where GlyR Zn2+ potentiation had
been eliminated. These results provide new insights into the
physiological modulatory mechanisms of glycinergic IPSCs.
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